Drug intelligence / Profile preview

T-001

Development stage: Unknown
Lead developer: Hangzhou Cheetah Cell Therapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies

Overview

**T-001** is an investigational CAR-NK (chimeric antigen receptor natural killer) cell therapy developed by Hangzhou Cheetah Cell Therapeutics for potential use in oncology. It functions as an **NKG2D antagonist**, targeting the NKG2D receptor to modulate immune responses against cancer cells. Limited public data is available, with no disclosed clinical trial phases, indications, or detailed efficacy results as of current knowledge.

Other names: T001 for InjectionT-001 for InjectionT 001 for InjectionT001注射液

Targets

MICB (Major histocompatibility complex class i-related protein B)

Beyond the preview

Go deeper on T-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-001.

Explore the full profile